REDMOND, Wash., Oct. 12, 2023 /PRNewswire/ — SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the first patient was treated on October 10th, 2023 with BL-B01D1, a first-in-class bispecific antibody-drug conjugate targeting both EGFR and HER3, as…